Earnings Call Intelligence Subscribe
Home › Call Sheets › BSX › Q1'26
Call sheet · Q1'26

Boston Scientific (BSX)

Q1'26 earnings call · held April 22, 2026 · compared with the Q4'25 call · management-credibility review
6/12
Disclosure score
3 high, 3 medium, 2 low flags
Financial quality
Bottom line
The sleeper story everyone's missing is that WATCHMAN standalone procedures are collapsing while the market obsesses over EP share losses. Management admitted standalone WATCHMAN is weakening for the first time ever, but buried this in concomitant growth narratives. The binding constraint isn't competition or market dynamics - it's that their highest-margin, most defensible franchises (WATCHMAN standalone, core EP dominance) are showing structural cracks they didn't see coming. Mahoney quietly walked back the 10%+ LRP growth target while claiming confidence, saying it's 'likely an upside scenario at this point.' Most revealing quote: 'We're seeing pressure in the stand-alone WATCHMAN business, which historically has not been a challenge for us.' My view changes if they start disclosing specific WATCHMAN procedure mix numbers again and can show the standalone decline is temporary rather than structural.

The 30-second version

  • WATCHMAN standalone procedures are quietly collapsing while everyone focuses on EP share losses
  • Guide down is really about three core franchises all hitting walls simultaneously
  • They're quietly walking back the 10%+ LRP growth target while claiming confidence

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$5.286B (+15.9% YoY)$5.203B (+11.6% YoY)410 bps deceleration
Organic Revenue Growth12.7%9.4%330 bps deceleration
Adjusted EPS$0.80 (+15%)$0.80 (+6%)900 bps deceleration
WATCHMAN Growth29%19%1,000 bps deceleration
EP Growth35%22%1,300 bps deceleration
Urology Growth13% in Q41%1,200 bps deceleration
US EP GrowthNot specified but strong18%Flat sequential quarters
Full Year Revenue Guide10% to 11%6.5% to 8%250-300 bps cut
Full Year EPS Guide$3.43 to $3.49$3.34 to $3.41$0.08 midpoint cut
Adjusted Gross Margin70.7%70.5%20 bps decline

Accountability tracked

8 new promises made6 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BSX Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.